Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: April 27, 2006
- Previous Holding: 17,507,831 ADRs
- New Holding: 17,432,485 ADRs
- Transaction Price: $53.01
- Net Change: Decrease of 75,346 ADRs
This change resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Directors Dr. J.P. Garnier and Dr. T. Yamada are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a specific transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the 75,346 ADR reduction on the total share count of the US Retirement Savings Plan.
- Confirm the potential interest status of Directors Dr. J.P. Garnier and Dr. T. Yamada regarding the fund's holdings.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial metrics.